Authors
Latest:
Margaret Moline, PhD: Next-Morning Residual Effects of Lemborexant in InsomniaThe International Project Team Lead spoke about the results of study endpoints that assessed the potential for next-morning residual effects of lemborexant, which is in development for insomnia.
Latest:
Navigating Insurance and Access Issues in MigraineCurrent hurdles faced by neurologists when prescribing therapy to treat migraine and advice to help other healthcare professionals as well as patients navigate insurance and access issues.
Latest:
Importance of Multidisciplinary Care in Management of Neurofibromatosis Type 1 Related Plexiform NeurofibromaKaleb Yohay, MD, an expert in NF1-PN, emphasizes the importance of multidisciplinary and comprehensive team care in managing the condition, detailing the essential team members required to facilitate a successful transition from adolescent to adult care.
Latest:
Uri Kramer, MD: Treating Epilepsy With CannabisThe professor of pediatrics at Tel Aviv University explained what has been fleshed out by the research and shared his opinion on cannabidiol’s use.
Latest:
Researching Dravet Syndrome Biomarkers to Advance Treatment: Christos Papadelis, PhDThe director of research in the Jane and John Justin Neurosciences Center at Cook Children's Health Care System talked about ongoing research on biomarkers to enhance treatment and improve cognitive outcomes. [WATCH TIME: 6 minutes]
Latest:
Sarah Wilson, PhD: Long-Term Social Outcomes of Epilepsy SurgeryThe clinical neuropsychologist and head of the School of Psychological Sciences at the University of Melbourne discussed the results of a study she and colleagues conducted in which they mapped the long-term social outcomes of patient post-epilepsy surgery.
Latest:
Conversations With Patients About Mild/Moderate Multiple SclerosisThe expert panel examines early multiple sclerosis (MS) and patients with mild MS even in later stages of the disease, emphasizing crucial information to convey to patients throughout their journey; faculty also explore cases where disease-modifying therapies (DMTs) may not be utilized.
Latest:
Multidisciplinary Care in Duchenne Muscular DystrophyEmma Ciafaloni, MD, addresses the important role of multidisciplinary care in the treatment of patients with Duchenne muscular dystrophy.
Latest:
Highly Effective Gene Therapies for SMA: Where Do We Go From Here?Neuromuscular medicine has entered an era of genetic therapy, opening the doors to questions about possible combination approaches and earlier initiation of treatment.
Latest:
Dravet Syndrome: Transition of Care Into AdulthoodJoseph Sullivan, MD, and Elaine C. Wirrell, discuss the transition of care into adulthood of patients with Dravet syndrome.
Latest:
Conversations About Off Time In Patients With Parkinson DiseasePanelists discuss how physicians approach conversations about off time with patients with Parkinson disease, balancing clinical assessment with patient education and shared decision-making.
Latest:
Future Directions in Research and TreatmentLooking to the future of multiple sclerosis care, the panel of thought leaders pose important questions that remain to be answered in the research and treatment of multiple sclerosis.
Latest:
Fred Rincon, MD, MSc: Increasing Use of Mobile Stroke UnitsThe chief of cerebrovascular disease at Jefferson University Hospitals detailed the importance and growth of mobile stroke units.
Latest:
Peter LeWitt, MD: Enhancing the Understanding of Parkinson for Therapeutic DevelopmentThe director of Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital discussed this pipeline of therapies and the enhancement of the clinical understanding of the disease.
Latest:
Intellectual and Electrophysiological Disturbances in the Definition of ‘Seizure’: Michael Sperling, MDAt the 2022 AES Conference, the Baldwin Keyes professor of neurology at Thomas Jefferson University talked about how clinicians and patients might define a seizure. [WATCH TIME: 3 minutes]
Latest:
Claudia Testa, MD, PhD: Pairing Huntington Disease TreatmentsThe professor of neurology at VCU spoke about the possibility of pairing gene therapies for Huntington disease down the line when they are available.
Latest:
Question and Answer about Neurofilament Light Chain and Other MS BiomarkersMark Freedman, MD, MSc, Tanuja Chitnis, MD, and Ahmed Obeidat, MD, PhD, answer questions about biomarkers in MS care.
Latest:
FDA Grants Alzheimer Biomarker Test Breakthrough StatusThe FDA has granted a Breakthrough Device Designation to the Elecsys beta-Amyloid (1-42) and Elecsys Phospho-Tau (181P) cerebrospinal fluid assays, which can be used in the diagnosis of Alzheimer disease.
Latest:
Paula E. Voinescu, MD, PhD: Seizure Frequency in Pregnancy, PostpartumThe attending neurologist at Brigham and Women's Hospital spoke about how seizure frequency during pregnancy and postpartum varies by epilepsy type.
Latest:
Characteristics of and Prevention Methods for Cerebral Palsy: Bhooma Aravamuthan, MD, DPhilThe assistant professor of pediatric neurology at Washington University in St. Louis provided an overview of cerebral palsy and ways to reduce the risk of developing the condition. [WATCH TIME: 3 minutes]
Latest:
Harnessing Gamma Frequencies to Modulate Alzheimer Pathology: Ralph Kern, MD, MHScThe chief medical officer at Cognito Therapeutics provided a clinical overview on promising findings surrounding the company’s gamma sensory stimulation device in patients with Alzheimer disease. [WATCH TIME: 10 minutes]
Latest:
Highlights on Exploring Advances in Headache Medicine from AHS Scottsdale 2024: MaryAnn Mays, MDThe neurologist in the Headache Center at Cleveland Clinic shared her post perspective on the 2024 AHS Scottsdale meeting which highlighted advancements in headache medicine and the growing impact of the field on patient care. [WATCH TIME: 5 minutes]
Latest:
Changes in Themes Across Neurology Over the Years: Rebecca Gottesman, MD, PhD, FANA; Frances E. Jensen, MD, FACPThe president of the ANA and the chair of the annual meeting programming committee provided commentary on the advances in neurology and the shift in how clinicians approach and treat diseases once thought to be fatal. [WATCH TIME: 6 minutes]
Latest:
Greater Insights into Seizure Causes With Epilepsy Genetic Testing in Adults: Yi Li, MD, PhDThe clinical assistant professor of neurology at Stanford University talked about findings from a study on genetic testing in adults with epilepsy and the importance of access to genetic testing for this patient population. [WATCH TIME: 7 minutes]
Latest:
Developing Cell Therapy for Progressive MS: Jakob Dupont, MD, MAThe head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.
Latest:
The Clinical Pearls for Diagnosing and Treating NMOSD: Brian G. Weinshenker, MD, FRCPThe professor of neurology at the University of Virginia talked about the improvement and areas of unmet need in the diagnosis and treatment for neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
Latest:
Unanswered Questions, Challenges in Epilepsy Diets: Robyn Blackford, RD, LDNThe registered dietitian at Ann & Robert H. Lurie Children’s Hospital discussed the unknowns in terms of managing and prescribing diets for patients with epilepsy. [WATCH TIME 3 minutes]
Latest:
Elixirgen Therapeutics’ Bobcat mRNA Therapeutic for Duchenne Muscular Dystrophy: Aki KoThe chief executive officer at Elixirgen Therapeutics discussed the company’s mRNA as a promising therapeutic avenue for Duchenne muscular dystrophy. [WATCH TIME: 6 minutes]
Latest:
State of Multiple Sclerosis Research and Understanding of the Impact of Age and Sex: Nancy Sicotte, MDThe chair of the Department of Neurology at Cedars Sinai Medical Center discussed the prominent topics of research in multiple sclerosis and the need to learn more about age and sex. [WATCH TIME: 5 minutes]
Latest:
Diving Into the Potential of Monoclonal Antibodies for Alzheimer Disease Treatment: Gayatri Devi, MDThe clinical professor of neurology at Lenox Hill Hospital/Northwell Health talked about her experience with monoclonal antibodies for Alzheimer disease treatment as well as the challenges and risks associated with them. [WATCH TIME: 8 minutes]
